Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Sairiyo Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics
Details : Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : Cepharanthine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Sairiyo Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
